Aug. 28, 2024 |
|
Aug. 28, 2024 |
|
jRCT2031240307 |
KD6-287 Phase III Study |
|
KD6-287 Phase III Study |
Shinmura Yasuhiko |
||
KM Biologics Co., Ltd. |
||
1314-1 Kyokushi Kawabe, Kikuchi-shi, Kumamoto, Japan |
||
+81-968-37-4073 |
||
rinkai-jrct@kmbiologics.com |
||
Yamashita Masatoshi |
||
KM Biologics Co., Ltd. |
||
1314-1 Kyokushi Kawabe, Kikuchi-shi, Kumamoto, Japan |
||
+81-968-37-4073 |
||
rinkai-jrct@kmbiologics.com |
Recruiting |
Sept. 01, 2024 |
||
150 | ||
Interventional |
||
randomized controlled trial |
||
double blind |
||
active control |
||
parallel assignment |
||
prevention purpose |
||
(1) Healthy infants and children who can receive investigational products three times from 6 to <90 months of age |
||
(1) Has a history of Japanese encephalitis |
||
6month old over | ||
82month old under | ||
Both |
||
Prevention of Japanese encephalitis |
||
Primary vaccination series: Subcutaneously or intramuscularly inject KD6-287 0.5 mL twice at an interval of 7-28 days (for children below 3 years of age, 0.25 mL per dose) |
||
Seroconversion rate of neutralizing antibodies after the third dose |
||
KM Biologics Co., Ltd. |
Nihonbashi Sakura Clinic IRB | |
5F, Inamura Building, 1-9-2, Nihonbashikayabacho, Chuo-ku, Tokyo | |
+81-3-6661-9061 |
|
c-irb_ug@neues.co.jp | |
Not approval | |
No |
|
none |